NEW Zealand asthma device
specialist Adherium will
supply more than 5,500 of its
Smartinhalers for use in a global
independent clinical study being
overseen by the Medical Research
Institute of New Zealand (MRINZ).
The Novel START study is a
“Randomised Controlled Trial of
the efficacy and safety of an ICS/
LABA reliever therapy regimen in
asthma,” with the project spanning
New Zealand, Australia, the United
Kingdom and Italy.
As part of the study MRINZ will
monitor each randomised subject’s
compliance and inhaler use, with
Adherium’s Smartinhaler platform
used to capture the data “in an
objective and acurate manner”.The above article was sent to subscribers in Pharmacy Daily's issue from 03 Mar 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Mar 16
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.